Targeting COPA to Enhance Erdafitinib Sensitivity in FGFRâAltered Bladder Cancer
Sign Up to like & getrecommendations! Published in 2025 at "Advanced Science"
DOI: 10.1002/advs.202413209
Abstract: Fibroblast growth factor receptor (FGFR) family aberrations are common in urothelial cancer. The FGFR tyrosine kinase inhibitor erdafitinib has been approved for locally advanced or metastatic urothelial cancer with FGFR2/3 alterations. Despite the initial efficacy… read more here.
Keywords: cancer; fgfr; erdafitinib; altered bladder ... See more keywords